Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients PBMCs: Potential role for STAT-3 and NF-B signaling

Journal of Investigative Dermatology

Volumn 130, Issue 8, 2010, Pages 2110-2119

  Zhang, Chunlei ^a   Li, Baoqiang ^a   Zhang, Xiang ^a   Hazarika, Parul ^a   Aggarwal, Bharat B ^a   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CURCUMIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; STAT3 PROTEIN; SURVIVIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DNA BINDING; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 77954762181     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.86     Document Type: Article

References (57)

1. Aggarwal BB (2004) Nuclear factor-kB: the enemy within. Cancer Cell 6:203-208
2. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921
3. Ammon HP, Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57:1-7
4. Anand P, Kunnumakkara AB, Newman RA et al. (2007) Bioavailability of curcumin: problem and promises. Mol Pharm 4:807-818
5. Baron ED, Stevens SR (2003) Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther 16:303-310
6. Bernengo MG, Novelli M, Quaglino P et al. (2001) The relevance of the CD4+ CD26- subset in the identification of circulating Sezary cells. Br J Dermatol 144:125-135
7. Bharti AC, Donato N, Singh S et al. (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053-1062
8. Breuckmann F, von Kobyletzki G, Avermaete A et al. (2002) Efficacy of ultraviolet A1 phototherapy on the expression of bcl-2 in atopic dermatitis and cutaneous T-cell lymphoma in vivo: a comparison study. Photodermatol Photoimmunol Photomed 18:217-222
9. Cheng AL, Hsu CH, Lin JK et al. (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895-2900
10. Choudhuri T, Pal S, Das T et al. (2005) Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 Phase of cell cycle in a p53-dependent manner. JBiol Chem 280:20059-20068
11. Criscione VD, Weinstock MA (2007) Incidence of cutaneous T-cell lymphoma in the United States. 1973-2002. Arch Dermatol 143:854-859
12. Dhillon N, Aggarwal BB, Newman RA et al. (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491-4499
13. Dobbeling U (2007) Transcription factor profiling shows new ways towards new treatment options of cutaneous T cell lymphomas. CurrDrug Discov Technol 4:24-30
14. Duriez PJ, Shah G (1997) Cleavage of poly (ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 75:337-349
15. Duvic M, Foss FM (2007) Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol 34:S21-8
16. Duvic M, Hymes K, Heald P et al. (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. JClin Oncol 19:2456-2471 (Pubitemid 32391217)
17. Duvic M, Talpur R, Ni X et al. (2007) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109:31-39 (Pubitemid 46053039)
18. Eriksen KW, Kaltoft K, Mikkelsen G et al. (2001) Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15:787-793
19. Everett PC, Meyers JA, Makkinje A et al. (2007) Preclinical assessment of curcumin as a potential therapy for B-CLL. Am JHematol 82:23-30
20. Gootenberg JE, Ruscetti FW, Mier JW et al. (1981) Human CTCL and leukemia cell lines produce and respond to T cell growth factor. JExp Med 154:1403-1418
21. Heng MC, Song MK, Harker J et al. (2000) Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143:937-949
22. Huang MT, Smart RC, Wong CQ et al. (1988) Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 48:5941-5946
23. Huang MT, Lou YR, Ma W et al. (1994) Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 54:5841-5847
24. Jiang MC, Yang-Yen HF, Yen JJ et al. (1996) Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer 26:111-120
25. Kacinski BM, Flick M (2001) Apoptosis and cutaneous T cell lymphoma. Ann NY Acad Sci 941:194-199
26. Kim YH, Liu HL, Mraz-Gernhard S et al. (2003) Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139:857-866
27. Korsmeyer SJ (1992) Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80:879-886
28. Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199-225
29. LaCasse EC, Baird S, Korneluk RG et al. (1998) The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 17:3247-3259
30. Li L, Aggarwal BB, Shishodia S et al. (2004) Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101:2351-2362
31. Lopez-Lazaro M (2008) Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 52:S103-27
32. Manion MK, Hockenbery DM (2003) Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2(Suppl 1):S105-14
33. Meech SJ, Edelson R, Walsh P et al. (2001) Reversible resistance to apoptosis in cutaneous T cell lymphoma. Ann NY Acad Sci 941:46-58
34. Mitchell TJ, John S (2005) Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 114:301-312
35. Moragoda L, Jaszewski R, Majumdar AP (2001) Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 21:873-878
36. Nielsen M, Nissen MH, Gerwien J et al. (2002) Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood 99:973-977
37. Odot J, Albert P, Carlier A et al. (2004) In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int JCancer 111:381-387
38. Osella-Aate S, Zaccagna A, Savoia P et al. (2001) Expression of apoptosis markers on peripheral blood lymphocytes from patients with cutaneous T-cell lymphoma during extracorporeal photochemotherapy. JAm Acad Dermatol 44:40-47
39. Pal S, Choudhuri T, Chattopadhyay S et al. (2001) Mechanisms of curcumin-induced apoptosis of Ehrlichs ascites carcinoma cells. Biochem Biophys Res Com 288:658-665
40. Popovic M, Sarin PS, Robert-Gurroff M (1983) Isolation and transmission of human retrovirus (HTLV). Science 219:856-859
41. Porter AG, Janicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99-104
42. Ramachandran C, You W (1999) Differential sensitivity of human mammary epithelial and breast carcinoma cell lines to curcumin. BreastCancerRes Treat 54:269-278
43. Sharma RA, Euden SA, Platton SL et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10:6847-6854
44. Sharma RA, McLelland HR, Hill KA et al. (2001) Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894-1900
45. Sommer VH, Clemmensen OJ, Nielsen O et al. (2004) In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18:1288-1295
46. Sors A, Jean-Louis F, Pellet C et al. (2006) Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 107:2354-2363
47. Starkebaum G, Loughran TP, Waters CA et al. (1991) Establishment of an IL-2 independent human T-cell line possessing only the p70 IL-2 receptor. Int J Cancer 49:246-253
48. Tanaka T, Makita H, Ohnishi M et al. (1994) Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of beta-carotene. Cancer Res 54:4653-4659
49. Tourkina E, Gooz P, Oates JC et al. (2004) Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am JRespir Cell Mol Biol 31:28-35
50. Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8:409-422
51. Uddin S, Hussain AR, Manogaran PS et al. (2005) Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 24:7022-7030
52. Watson JL, Hill R, Lee PW et al. (2008) Curcumin induces apoptosis in HCT-116 human colon cancer cells in a p21-independent manner. Exp Mol Pathol 84:230-233
53. Zhang C, Hazarika P, Ni X et al. (2002) Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 8:1234-1240
54. Zhang C, Kamarashev J, Qin J et al. (2003) Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol 200:249-254
55. Zhang C, Li B, Gaikwad AS et al. (2008) Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. JInvest Dermatol 128:2728-2735
56. Zhang C, Richon V, Ni X et al. (2005) Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 125:1045-1052
57. Zic JA (2003) The treatment of cutaneous T-cell lymphoma with photopher-esis. Dermatol Ther 16:337-346